Please use this identifier to cite or link to this item: https://hdl.handle.net/1/855
Title: Peginesatide to manage Anemia in chronic kidney disease patients on peritoneal dialysis
Authors: Roger, Simon D ;Zabaneh, Raja;El-Shahawy, Mohamed;Roppolo, Michael;Runyan, Grant ;O'Neil, Janet ;Ping, Qiu
Issue Date: Jul-2015
Source: Volume 35, Issue 4, pp. 481-489
Journal title: Peritoneal Dialysis International
Abstract: BACKGROUND: Peginesatide is a novel, synthetic, peptide-based pegylated erythropoiesis-stimulating agent that is designed specifically to stimulate the erythropoietin receptor. The purpose of the present study was to assess, for the first time, the efficacy and safety of peginesatide in chronic kidney disease (CKD) patients receiving peritoneal dialysis (PD) and previously on epoetin treatment. ♦ METHODS: In this open-label multicenter study, 59 PD patients with CKD were converted from epoetin (alfa or beta) to once-monthly peginesatide. Doses were titrated to maintain hemoglobin levels between 10 g/dL and 12 g/dL during the 25 weeks of the study. The primary endpoint was change from baseline in mean hemoglobin values during the evaluation period (weeks 20 - 25). ♦ RESULTS: The mean hemoglobin value during the evaluation period was 11.3 ± 1.07 g/dL, and the mean change from baseline was 0.10 ± 1.15 g/dL (95% confidence limits: -0.24, 0.44 g/dL). During the evaluation period, most patients maintained hemoglobin levels between 10 g/dL and 12 g/dL (63.0%) and within ±1.0 g/dL of baseline (60.9%). The median weekly epoetin dose at baseline was 96.0 U/kg, and the median starting peginesatide dose was 0.047 mg/kg. Forty-three patients (72.9%) completed the study. Six patients (10.2%) received red blood cell transfusions. The observed adverse event profile was consistent with underlying conditions in the PD patient population. The most common adverse event was peritonitis (20.3%), a complication commonly associated with PD. Four deaths occurred during the study (2 related to septic shock, and 1 each to myocardial ischemia and myasthenia gravis). ♦ CONCLUSIONS: In this study, once-monthly peginesatide maintained hemoglobin levels in PD patients after conversion from epoetin.
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/855
DOI: 10.3747/pdi.2012.00224
Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/24584613
ISSN: 0896-8608
Publicaton type: Journal Article
Keywords: Kidney Disease
Drug Therapy
Study or Trial: Clinical Trial
Appears in Collections:Renal Medicine

Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.